Lineage Cell Therapeutics Inc (AMEX: LCTX) closed the day trading at $1.29 up 11.21% from the previous closing price of $1.16. In other words, the price has increased by $+0.1300 from its previous closing price. On the day, 1659783 shares were traded.
Ratios:
For a better understanding of LCTX, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.14 and its Current Ratio is at 2.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Robert W. Baird on November 02, 2022, initiated with a Outperform rating and assigned the stock a target price of $5.
On June 14, 2022, B. Riley Securities started tracking the stock assigning a Buy rating and target price of $4.
On August 19, 2021, Noble Capital Markets started tracking the stock assigning a Outperform rating and target price of $8.Noble Capital Markets initiated its Outperform rating on August 19, 2021, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 08 ’24 when BAILEY DON M bought 96,155 shares for $1.04 per share. The transaction valued at 100,001 led to the insider holds 158,801 shares of the business.
BROADWOOD PARTNERS, L.P. bought 6,730,770 shares of LCTX for $7,000,001 on Feb 06 ’24. The Director now owns 41,666,255 shares after completing the transaction at $1.04 per share. On Dec 29 ’23, another insider, Jayasuriya Anula, who serves as the Director of the company, bought 10,000 shares for $1.09 each. As a result, the insider paid 10,900 and bolstered with 10,000 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LCTX now has a Market Capitalization of 243.21M and an Enterprise Value of 210.67M. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.17 while its Price-to-Book (P/B) ratio in mrq is 3.56. Its current Enterprise Value per Revenue stands at 23.55 whereas that against EBITDA is -8.76.
Stock Price History:
Over the past 52 weeks, LCTX has reached a high of $1.57, while it has fallen to a 52-week low of $0.84. The 50-Day Moving Average of the stock is 1.1032, while the 200-Day Moving Average is calculated to be 1.2133.
Shares Statistics:
Over the past 3-months, LCTX traded about 874.13K shares per day on average, while over the past 10 days, LCTX traded about 1.09M shares per day. A total of 188.53M shares are outstanding, with a floating share count of 187.49M. Insiders hold about 0.55% of the company’s shares, while institutions hold 48.05% stake in the company. Shares short for LCTX as of Feb 29, 2024 were 9.62M with a Short Ratio of 11.01, compared to 8.46M on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 5.11% and a Short% of Float of 6.88%.
Earnings Estimates
Current recommendations for the stock of the company come from 6 analysts. On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.05, while EPS last year was -$0.03. The consensus estimate for the next quarter is -$0.04, with high estimates of -$0.03 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.01 and -$0.22 for the fiscal current year, implying an average EPS of -$0.12. EPS for the following year is -$0.13, with 6 analysts recommending between -$0.03 and -$0.23.
Revenue Estimates
Based on 6 analysts’ estimates, the company’s revenue will be $16.15M in the next fiscal year. The high estimate is $50M and the low estimate is $2.6M. The average revenue growth estimate for next year is down -12.70% from the average revenue estimate for this year.
